Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1998;29:2304-2310

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scott, P. A.
Right arrow Articles by Lowell, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scott, P. A.
Right arrow Articles by Lowell, M. J.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Emergency Medical Services

(Stroke. 1998;29:2304-2310.)
© 1998 American Heart Association, Inc.


Original Contributions

Analysis of Canadian Population With Potential Geographic Access to Intravenous Thrombolysis for Acute Ischemic Stroke

Phillip A. Scott, MD; Chris J. Temovsky, HBSc; Kate Lawrence, MBBS, MPH, MFPHM; Edward Gudaitis, MBA; Mark J. Lowell, MD

From the Section of Emergency Medicine, Department of Surgery, University of Michigan Medical Center, Ann Arbor, Mich (P.A.S., M.J.L.), and Hoffmann-La Roche, Ltd (Canada), Toronto, Canada (C.J.T., K.L., E.G.).

Correspondence to Phillip A. Scott, MD, University of Michigan Medical Center, Section of Emergency Medicine, TC B1354, Box 0303, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0303. E-mail phillip.scott{at}umich.edu

Background and Purpose—We sought to identify the Canadian population with potential access to intravenous tissue plasminogen activator within 3 hours of onset of acute ischemic stroke.

Methods—Assuming that 60 minutes is needed for stroke recognition, emergency room evaluation, and administration of tissue plasminogen activator, 120 minutes remain for transport, using a 3-hour treatment window. Ambulance databases were analyzed for transport times of 60, 90, and 120 minutes and were found to correspond to transport distances of 32, 64, and 105 kilometers (20, 40, and 65 miles), respectively. Using Geographical Information System (GIS) software, these radii were overlaid on thematic maps of Canadian hospitals identified as having a third- or fourth-generation CT and with a neurologist and an emergency physician on staff. Analysis was then performed on complete Canadian census data from 1991 and the interim 1996 census count.

Results—67.3%, 78.2%, and 85.3% of the total Canadian population were within 32, 64, and 105 kilometers, respectively, of an identified hospital. For individuals >=65 years of age, 64.4%, 77.0%, and 85.7% were within the respective radii. Complete analysis by age, ethnic origin, and gender are detailed.

Conclusions—In the model described, a substantial percentage of the Canadian population has geographic access to a hospital potentially capable of delivering intravenous thrombolysis for acute ischemic stroke. GIS analysis can identify both population groups and rural areas with limited access to thrombolytic stroke treatment. A coordinated emergency medical service response for stroke is advocated to maximize coverage, as a 60-minute delay in emergency room arrival eliminated 5.1 million people from potential treatment.


Key Words: epidemiology • geography • stroke, acute




This article has been cited by other articles:


Home page
CMAJHome page
M. D. Hill, A. M. Buchan, and for The Canadian Alteplase for Stroke Effectivenes
Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study
Can. Med. Assoc. J., May 10, 2005; 172(10): 1307 - 1312.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. G. Merino, B. Silver, E. Wong, B. Foell, B. Demaerschalk, A. Tamayo, F. Poncha, and V. Hachinski
Extending Tissue Plasminogen Activator Use to Community and Rural Stroke Patients
Stroke, January 1, 2002; 33(1): 141 - 146.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. M. Chapman, A. R. Woolfenden, D. Graeb, D. C. C. Johnston, J. Beckman, M. Schulzer, and P. A. Teal
Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke : A Canadian Hospital's Experience
Stroke, December 1, 2000; 31(12): 2920 - 2924.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. B. Conroy, S. U. Rodriguez, S. E. Kimmel, and S. E. Kasner
Helicopter Transfer Offers a Potential Benefit to Patients With Acute Stroke
Stroke, December 1, 1999; 30(12): 2580 - 2584.
[Abstract] [Full Text] [PDF]